Shang­hai's Ab­bisko out-li­cens­es EGFR can­di­date in po­ten­tial­ly nine-fig­ure deal

A Shang­hai-based biotech is hand­ing off rights to one of its can­di­dates to an­oth­er Shang­hai com­pa­ny.

Qim­ing-backed Ab­bisko — head­ed by Eli Lil­ly and No­var­tis vet­er­an Yao-Chang Xu — said Wednes­day that it would be out-li­cens­ing its can­di­date ABK3376 to Al­list Phar­ma­ceu­ti­cals. The small mol­e­cule is a pre­clin­i­cal, brain-pen­e­trant EGFR in­hibitor which can in­hib­it dif­fer­ent mu­ta­tions such as L858R ac­ti­vat­ing mu­ta­tion or the ex­on 19 dele­tion mu­ta­tion, Ab­bisko said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER